Matthew J Perkins1, William P Bradley, Tahaniyat Lalani, Brian K Agan, Timothy J Whitman, Tomas M Ferguson, Jason F Okulicz, Anuradha Ganesan. 1. *Infectious Disease Service, Walter Reed National Military Medical Center, Bethesda, MD; †Infectious Disease Clinical Research Program, Rockville, MD; ‡Henry M Jackson Foundation for the Advancement of Military Medicine, Rockville, MD; §Infectious Disease Service, San Antonio Military Medical Center, San Antonio, TX; ‖Infectious Disease Service, Naval Medical Center Portsmouth, Portsmouth, VA; and ¶Infectious Disease Service, Tripler Army Medical Center, Honolulu, HI.
Abstract
BACKGROUND: Posttreatment control of HIV infection is a rare phenomenon primarily described among those initiating treatment with antiretroviral therapy (ART) during early/acute HIV infection. METHODS: We examined a large, well-characterized cohort of HIV-infected Department of Defense beneficiaries for the presence of posttreatment controllers (PTCs) whom we defined as individuals with sustained viral suppression for ≥6 months after discontinuation of ART. We defined those who became viremic within 6 months of discontinuing ART as rapid viremics (RVs) and compared demographic and clinical characteristics, CD4 counts, and viral loads prior, during, and after ART discontinuation between the 2 groups. RESULTS: From a cohort of 6070 patients, we identified 95 who had been treated with ART for 2 years or more who subsequently discontinued ART and had viral load assessments available after discontinuation. Four (4.2%) of these 95 met our definition of PTC. The duration of viral suppression off of ART ranged from 267 to 1058 days with 1 of the 4 restarting ART without having redeveloped a significant viremia. All 4 patients initiated ART during chronic HIV infection. Demographic and clinical characteristics of PTCs were similar to RVs. CONCLUSIONS: While posttreatment control has predominantly been described among individuals who initiated ART in early/acute HIV infection, we identified 4 PTCs who started ART during chronic infection suggesting that posttreatment control also occurs among such patients. The rarity of PTCs identified in our cohort is consistent with reports from previous studies.
BACKGROUND: Posttreatment control of HIV infection is a rare phenomenon primarily described among those initiating treatment with antiretroviral therapy (ART) during early/acute HIV infection. METHODS: We examined a large, well-characterized cohort of HIV-infected Department of Defense beneficiaries for the presence of posttreatment controllers (PTCs) whom we defined as individuals with sustained viral suppression for ≥6 months after discontinuation of ART. We defined those who became viremic within 6 months of discontinuing ART as rapid viremics (RVs) and compared demographic and clinical characteristics, CD4 counts, and viral loads prior, during, and after ART discontinuation between the 2 groups. RESULTS: From a cohort of 6070 patients, we identified 95 who had been treated with ART for 2 years or more who subsequently discontinued ART and had viral load assessments available after discontinuation. Four (4.2%) of these 95 met our definition of PTC. The duration of viral suppression off of ART ranged from 267 to 1058 days with 1 of the 4 restarting ART without having redeveloped a significant viremia. All 4 patients initiated ART during chronic HIV infection. Demographic and clinical characteristics of PTCs were similar to RVs. CONCLUSIONS: While posttreatment control has predominantly been described among individuals who initiated ART in early/acute HIV infection, we identified 4 PTCs who started ART during chronic infection suggesting that posttreatment control also occurs among such patients. The rarity of PTCs identified in our cohort is consistent with reports from previous studies.
Authors: Meghan K Rothenberger; Brandon F Keele; Stephen W Wietgrefe; Courtney V Fletcher; Gregory J Beilman; Jeffrey G Chipman; Alexander Khoruts; Jacob D Estes; Jodi Anderson; Samuel P Callisto; Thomas E Schmidt; Ann Thorkelson; Cavan Reilly; Katherine Perkey; Thomas G Reimann; Netanya S Utay; Krystelle Nganou Makamdop; Mario Stevenson; Daniel C Douek; Ashley T Haase; Timothy W Schacker Journal: Proc Natl Acad Sci U S A Date: 2015-02-23 Impact factor: 11.205
Authors: Jason F Okulicz; Vincent C Marconi; Michael L Landrum; Scott Wegner; Amy Weintrob; Anuradha Ganesan; Braden Hale; Nancy Crum-Cianflone; Judith Delmar; Vincent Barthel; Gerald Quinnan; Brian K Agan; Matthew J Dolan Journal: J Infect Dis Date: 2009-12-01 Impact factor: 5.226
Authors: Helen M Chun; Ann M Fieberg; Katherine Huppler Hullsiek; Alan R Lifson; Nancy F Crum-Cianflone; Amy C Weintrob; Anuradha Ganesan; Robert V Barthel; William P Bradley; Brian K Agan; Michael L Landrum Journal: Clin Infect Dis Date: 2010-02-01 Impact factor: 9.079
Authors: Ellen Van Gulck; Leo Heyndrickx; Lotte Bracke; Sandra Coppens; Eric Florence; Anne Buvé; Paul Lewi; Guido Vanham Journal: AIDS Res Ther Date: 2011-02-11 Impact factor: 2.250
Authors: Ellen Van Gulck; Lotte Bracke; Leo Heyndrickx; Sandra Coppens; Derek Atkinson; Céline Merlin; Alexander Pasternak; Eric Florence; Guido Vanham Journal: PLoS One Date: 2012-05-30 Impact factor: 3.240
Authors: Genevieve E Martin; Morgane Gossez; James P Williams; Wolfgang Stöhr; Jodi Meyerowitz; Ellen M Leitman; Philip Goulder; Kholoud Porter; Sarah Fidler; John Frater Journal: AIDS Date: 2017-02-20 Impact factor: 4.177
Authors: Avy Violari; Mark F Cotton; Louise Kuhn; Diana B Schramm; Maria Paximadis; Shayne Loubser; Sharon Shalekoff; Bianca Da Costa Dias; Kennedy Otwombe; Afaaf Liberty; James McIntyre; Abdel Babiker; Diana Gibb; Caroline T Tiemessen Journal: Nat Commun Date: 2019-01-24 Impact factor: 14.919
Authors: Csaba Fehér; Lorna Leal; Montserrat Plana; Nuria Climent; Alberto Crespo Guardo; Esteban Martínez; Pedro Castro; Vicens Díaz-Brito; Beatriz Mothe; Juan Carlos López Bernaldo De Quirós; Josep María Gatell; Patrick Aloy; Felipe García Journal: Open Forum Infect Dis Date: 2019-11-03 Impact factor: 3.835